-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S2/obMNHf6VnMjodsZ+mhUiuqiyAGYQsyWfWRLgW3HSFyq5bXvPPmYW9/xqyTS0F OSfKdtob8nx62hGHEhB54Q== 0001144204-04-022960.txt : 20041229 0001144204-04-022960.hdr.sgml : 20041229 20041228174634 ACCESSION NUMBER: 0001144204-04-022960 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041223 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20041229 DATE AS OF CHANGE: 20041228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RITA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0001056421 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943199149 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30959 FILM NUMBER: 041229227 BUSINESS ADDRESS: STREET 1: 967 N SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94013 BUSINESS PHONE: 6503858500 MAIL ADDRESS: STREET 1: 967 NORTH SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 8-K 1 form8k.htm Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 23, 2004

RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

000-30959
(Commission File Number)

Delaware

94-3199149

(State or other jurisdiction of incorporation)

 (I.R.S. Employer Identification No.)

 
967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)

(650) 314-3400
(Registrant's telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
  o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

     

 

 
Item 1.01  Entry into a Material Definitive Agreement.

On December 23, 2004, RITA Medical Systems, Inc. (the “Company”) entered into a Waiver and Amendment Agreement (the “Agreement”) with SF Capital Partners Ltd. (“SF Capital”) and BayStar Capital II, L.P. (“BayStar”). The Company is party to certain Stock and Warrant Purchase Agreements dated November 24, 2004 (the “Purchase Agreements”) with each of SF Capital, BayStar, Walker Smith Capital (and its affiliates) (“Walker Smith”) and Capital Ventures International (“CVI”). Pursuant to the terms of the Purchase Agreements, the Company sold shares of its common stock (the “Shares”) and warrants to purchase shares of its common stock to each of SF Capital, BayStar, Walker Smith and CVI.

Pursuant to the Agreement, SF Capital and BayStar, which together hold a majority of the Shares, agreed, among other things (i) to waive certain provisions of the Purchase Agreements and (ii) to amend the Purchase Agreements to extend the Expiration Date (as defined in the Purchase Agreements) to January 14, 2005.

The description of the terms and conditions of the Agreement set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement attached hereto as Exhibit 10.79 and incorporated herein by reference.


     

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


RITA MEDICAL SYSTEMS, INC.


Date: December 28, 2004        By: /s/ Donald Stewart_________
Donald Stewart
Chief Financial Officer


     

 

EXHIBIT INDEX
 
     
Exhibit No.
 
Description
   
10.79
 
Waiver and Amendment Agreement dated as of December 23, 2004 by and among RITA Medical Systems, Inc., SF Capital Partners Ltd. and BayStar Capital II, L.P.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EX-10.79 2 ex10_79.htm Unassociated Document

WAIVER AND AMENDMENT AGREEMENT

THIS WAIVER AND AMENDMENT AGREEMENT (“Agreement”) is made as of December 23, 2004 by and among RITA Medical Systems, Inc., a Delaware corporation (“RITA”), SF Capital Partners Ltd. (“SF Capital”) and BayStar Capital II, L.P. (“BayStar”).

RECITALS

A. RITA, SF Capital and BayStar are parties to those certain Stock and Warrant Purchase Agreements by and between RITA on one hand and SF Capital, BayStar and other investors identified therein on the other hand (collectively, the “Investors”), dated as of November 24, 2004 (collectively, the “Purchase Agreements”).

B. Section 9 of the Purchase Agreements provide, in part, that the Purchase Agreements may be modified, amended or waived only pursuant to a written instrument signed by RITA and Investors holding a majority of the Shares (as defined in the Purchase Agreements) issued and sold in the Offering (as defined in the Purchase Agreements) (the “Majority Investors”).

C. SF Capital and BayStar together constitute the Majority Investors.

AGREEMENT

NOW, THEREFORE, in consideration of the above recitals, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

1. Waiver. Notwithstanding any provision in the Purchase Agreements to the contrary, SF Capital and BayStar, representing the Majority Investors, hereby waive the requirement in Section 4.11 that on or prior to 30 calendar days after the Closing Date, the information set forth in the Disclosure Schedules either (i) be publicly disclosed by the Company or (ii) no longer constitute material non-public information.

2. Amendment. The definition of “Expiration Date” as used in the Purchase Agreements is hereby amended and restated to mean “January 14, 2005”. Accordingly, the information in the Disclosure Schedules shall either (i) be publicly disclosed on or prior to January 14, 2005 or (ii) no longer constitute non-public information on or prior to January 14, 2005. Furthermore, each Investor agrees that between the time the Investor learned about the Offering and the Expiration Date, the Investor has not engaged in any transaction (including short sales or similar transactions) with respect to the Common Stock, nor has the Investor, directly or indirectly, caused any person to engage in any transaction (including short sales or similar transactions) with respect to the Common Stock.


 
     

 


3. Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to the principles of conflicts of law.

4. Capitalized Terms. Capitalized terms not defined in this Agreement shall having the meaning attributed to them in the Purchase Agreements.

5. Continuing Effect. Except as expressly provided for herein, the Purchase Agreements shall continue to be, and shall remain, in full force and effect in accordance with their terms.

6. Counterparts. This Agreement may be executed in any number of identical counterparts, including by electronic or facsimile transmission, any set of which signed by all the parties hereto shall be deemed to constitute a complete, executed original for all purposes.

7. Successors and Assigns. All the terms and provisions of this Agreement shall be binding and inure to the benefit of the respective successors and assigns of RITA and the Investors.

[Signature Pages Follow]


 
     

 


IN WITNESS WHEREOF, the undersigned parties have caused this Waiver and Amendment Agreement to be duly executed by their respective officers thereunto duly authorized, as of the date first above written.



HORIZON MEDICAL PRODUCTS, INC.

By: /s/ Donald Stewart

Name: Donald Stewart
Title: Chief Financial Officer


SF CAPITAL PARTNERS LTD.

By: /s/ Brian Dawson

Name: Brian Dawson
Title: Authorized Signatory


BAYSTAR CAPITAL II, L.P.

By: /s/ Steven H. Lamar

Name: Steven H. Lamar
Title: Managing Partner






[Signature Page to Waiver and Amendment Agreement]
-----END PRIVACY-ENHANCED MESSAGE-----